Furthermore, LMF treatment reversed the DNA hypomethylation/hypermethylation ratio in LMF-treated patients (515 hypomethylated to 645 hypermethylated CpGs) compared with that found in LGG transition to secondary (IDH-mutant) GBM (4,343 hypomethylated to 311 hypermethylated CpGs) and primary (IDH-wild-type) GBM recurrence (785 hypomethylated to 124 hypermethylated CpGs; ref. 9). The gene discussed is IDH2; the disease is glioblastoma.